Business
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with pati
About this update from Nanjing Leads Biolabs Co., Ltd. Class H
[{"type":"image","alt":"Dianthus Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dianthus Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/61491946bd3021c517ffff2a15860063"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ixt2UH4SsSj4u6F3w6SSew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/61491946bd3021c517ffff2a15860063","width":300,"height":57}},"lazy":false},{"type":"text","content":"DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function ","length":201,"tagName":"p"},{"type":"text","content":"Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases","length":201,"tagName":"p"},{"type":"text","content":"DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less frequent dosing","length":165,"tagName":"p"},{"type":"text","content":"IND cleared by FDA in September 2025 and expected to clear in China in Q4’25. Phase 1 study of DNTH212 expected to initiate in Q4’25 with top-line results in healthy volunteers in 2H’26","length":185,"tagName":"p"},{"type":"text","content":"Pro forma estimated cash of ~$525 million; reaffirms runway into 2028","length":69,"tagName":"p"},{"type":"text","content":"Investor conference call and webcast to be held today at 8:00 a.m. ET ","length":69,"tagName":"p"},{"type":"text","content":"NEW YORK and WALTHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced it has entered into an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. (“Leads” (9887.HK) for DNTH212 (being developed in China by Leads Biolabs as LBL-047), a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor.","length":529,"tagName":"p"},{"type":"text","content":"DNTH212 is...